Switch to:
Also traded in: Germany, Sweden, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.38
SWTUY's Cash to Debt is ranked lower than
60% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.70 vs. SWTUY: 1.38 )
Ranked among companies with meaningful Cash to Debt only.
SWTUY' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.73 Max: No Debt
Current: 1.38
Equity to Asset 0.59
SWTUY's Equity to Asset is ranked lower than
56% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. SWTUY: 0.59 )
Ranked among companies with meaningful Equity to Asset only.
SWTUY' s Equity to Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.71 Max: 0.77
Current: 0.59
0.48
0.77
Interest Coverage 6.25
SWTUY's Interest Coverage is ranked lower than
74% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 41.98 vs. SWTUY: 6.25 )
Ranked among companies with meaningful Interest Coverage only.
SWTUY' s Interest Coverage Range Over the Past 10 Years
Min: 1.31  Med: 2.18 Max: 9999.99
Current: 6.25
1.31
9999.99
F-Score: 7
Z-Score: 6.16
M-Score: -2.77
WACC vs ROIC
12.47%
7.46%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 12.51
SWTUY's Operating margin (%) is ranked higher than
79% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.99 vs. SWTUY: 12.51 )
Ranked among companies with meaningful Operating margin (%) only.
SWTUY' s Operating margin (%) Range Over the Past 10 Years
Min: -16.67  Med: 0.36 Max: 4.54
Current: 12.51
-16.67
4.54
Net-margin (%) 8.42
SWTUY's Net-margin (%) is ranked higher than
74% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.63 vs. SWTUY: 8.42 )
Ranked among companies with meaningful Net-margin (%) only.
SWTUY' s Net-margin (%) Range Over the Past 10 Years
Min: -29.4  Med: -1.67 Max: 7.72
Current: 8.42
-29.4
7.72
ROE (%) 6.48
SWTUY's ROE (%) is ranked higher than
60% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.04 vs. SWTUY: 6.48 )
Ranked among companies with meaningful ROE (%) only.
SWTUY' s ROE (%) Range Over the Past 10 Years
Min: -24.5  Med: -0.78 Max: 6
Current: 6.48
-24.5
6
ROA (%) 4.18
SWTUY's ROA (%) is ranked higher than
68% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.78 vs. SWTUY: 4.18 )
Ranked among companies with meaningful ROA (%) only.
SWTUY' s ROA (%) Range Over the Past 10 Years
Min: -14.82  Med: -0.60 Max: 3.92
Current: 4.18
-14.82
3.92
ROC (Joel Greenblatt) (%) 79.36
SWTUY's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.88 vs. SWTUY: 79.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SWTUY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -56.55  Med: -3.81 Max: 28.33
Current: 79.36
-56.55
28.33
Revenue Growth (3Y)(%) 18.50
SWTUY's Revenue Growth (3Y)(%) is ranked higher than
83% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. SWTUY: 18.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SWTUY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -34.3  Med: -9.40 Max: 18.5
Current: 18.5
-34.3
18.5
» SWTUY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with SWTUY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LSE:0H1Z, NYSE:BIO, NAS:BRKR, NYSE:CRL, NAS:VWR » details
Traded in other countries:B6E.Germany, SOBI.Sweden, 0MTD.UK,
Swedish Orphan Biovitrum AB is an international speciality healthcare company dedicated to rare diseases. The Company's Therapeutic Areas are Inflammation and Genetics & Metabolism, with a growing focus on Haemophilia and Neonatology.

Swedish Orphan Biovitrum AB is a Sweden-based pharmaceutical company that markets specialist pharmaceuticals. Its research and development is focused on the development and production of biotechnology therapeutics within the areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care, and malabsorption. The company produces specialist pharmaceuticals that are intended to target small patient groups and are prescribed by medical specialists, as well as biopharmaceuticals, recombinant proteins produced using biotechnological processes similar to the body's own substances. The company develops its products either internally, or through partnerships with other pharmaceutical companies. Biovitrium promotes its proprietary products and prescription specialist products throughout Europe, North America, Australia, and New Zealand, in collaboration with Wyeth, Amgen, and other pharmaceutical and biotechnology comapanies. The company's pipeline includes the following products: Kepivance, a recombinant protein drug used to prevent inflammation and ulcers of the oral mucosa in patients suffering from hematologic cancer; Kiobrina, a recombinant human lipid-digesting enzyme (BSSL) for the purpose of improving fat absorption and increasing growth in premature infants; Exinalda, a biotechnologically produced recombinant human enzyme to improve treatment for patients suffering from fat malabsorption due to pancreatic insufficiency in diseases such as cystic fibrosis (CF); Factor IX Fc, a recombinant protein drug developed in combination with Biogen Idec for the treatment of hemophilia B, to name a few.

Ratios

vs
industry
vs
history
P/E(ttm) 99.47
SWTUY's P/E(ttm) is ranked lower than
95% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.05 vs. SWTUY: 99.47 )
Ranked among companies with meaningful P/E(ttm) only.
SWTUY' s P/E(ttm) Range Over the Past 10 Years
Min: 21.64  Med: 167.18 Max: 523.95
Current: 99.47
21.64
523.95
Forward P/E 29.24
SWTUY's Forward P/E is ranked lower than
68% of the 41 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.33 vs. SWTUY: 29.24 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 99.47
SWTUY's PE(NRI) is ranked lower than
95% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.16 vs. SWTUY: 99.47 )
Ranked among companies with meaningful PE(NRI) only.
SWTUY' s PE(NRI) Range Over the Past 10 Years
Min: 21.76  Med: 171.58 Max: 1830
Current: 99.47
21.76
1830
Price/Owner Earnings (ttm) 43.47
SWTUY's Price/Owner Earnings (ttm) is ranked lower than
72% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.47 vs. SWTUY: 43.47 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
SWTUY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 38.41  Med: 67.84 Max: 1236.84
Current: 43.47
38.41
1236.84
P/B 6.05
SWTUY's P/B is ranked lower than
78% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. SWTUY: 6.05 )
Ranked among companies with meaningful P/B only.
SWTUY' s P/B Range Over the Past 10 Years
Min: 0.71  Med: 3.77 Max: 8.05
Current: 6.05
0.71
8.05
P/S 8.36
SWTUY's P/S is ranked lower than
77% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.95 vs. SWTUY: 8.36 )
Ranked among companies with meaningful P/S only.
SWTUY' s P/S Range Over the Past 10 Years
Min: 1.07  Med: 5.42 Max: 12.77
Current: 8.36
1.07
12.77
PFCF 70.91
SWTUY's PFCF is ranked lower than
87% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.05 vs. SWTUY: 70.91 )
Ranked among companies with meaningful PFCF only.
SWTUY' s PFCF Range Over the Past 10 Years
Min: 12.24  Med: 103.97 Max: 762.31
Current: 70.91
12.24
762.31
POCF 53.16
SWTUY's POCF is ranked lower than
90% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.45 vs. SWTUY: 53.16 )
Ranked among companies with meaningful POCF only.
SWTUY' s POCF Range Over the Past 10 Years
Min: 10.22  Med: 50.40 Max: 1072.22
Current: 53.16
10.22
1072.22
EV-to-EBIT 67.68
SWTUY's EV-to-EBIT is ranked lower than
94% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.15 vs. SWTUY: 67.68 )
Ranked among companies with meaningful EV-to-EBIT only.
SWTUY' s EV-to-EBIT Range Over the Past 10 Years
Min: -600.4  Med: -34.05 Max: 627.6
Current: 67.68
-600.4
627.6
EV-to-EBITDA 38.56
SWTUY's EV-to-EBITDA is ranked lower than
86% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.21 vs. SWTUY: 38.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
SWTUY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -600.4  Med: 15.25 Max: 1429.9
Current: 38.56
-600.4
1429.9
Current Ratio 2.13
SWTUY's Current Ratio is ranked lower than
60% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. SWTUY: 2.13 )
Ranked among companies with meaningful Current Ratio only.
SWTUY' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 2.59 Max: 3.23
Current: 2.13
1.67
3.23
Quick Ratio 1.48
SWTUY's Quick Ratio is ranked lower than
70% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. SWTUY: 1.48 )
Ranked among companies with meaningful Quick Ratio only.
SWTUY' s Quick Ratio Range Over the Past 10 Years
Min: 0.66  Med: 1.49 Max: 1.89
Current: 1.48
0.66
1.89
Days Inventory 233.49
SWTUY's Days Inventory is ranked lower than
92% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.76 vs. SWTUY: 233.49 )
Ranked among companies with meaningful Days Inventory only.
SWTUY' s Days Inventory Range Over the Past 10 Years
Min: 84.33  Med: 310.58 Max: 566.37
Current: 233.49
84.33
566.37
Days Sales Outstanding 50.68
SWTUY's Days Sales Outstanding is ranked higher than
64% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SWTUY: 50.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
SWTUY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 10.26  Med: 55.08 Max: 73.93
Current: 50.68
10.26
73.93
Days Payable 55.54
SWTUY's Days Payable is ranked lower than
52% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 56.90 vs. SWTUY: 55.54 )
Ranked among companies with meaningful Days Payable only.
SWTUY' s Days Payable Range Over the Past 10 Years
Min: 43.2  Med: 105.01 Max: 198.48
Current: 55.54
43.2
198.48

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 6.07
SWTUY's Price/Projected FCF is ranked lower than
88% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. SWTUY: 6.07 )
Ranked among companies with meaningful Price/Projected FCF only.
SWTUY' s Price/Projected FCF Range Over the Past 10 Years
Min: 4.45  Med: 6.11 Max: 8.54
Current: 6.07
4.45
8.54
Price/Median PS Value 1.54
SWTUY's Price/Median PS Value is ranked lower than
84% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. SWTUY: 1.54 )
Ranked among companies with meaningful Price/Median PS Value only.
SWTUY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 0.99 Max: 2.06
Current: 1.54
0.21
2.06
Earnings Yield (Greenblatt) (%) 1.44
SWTUY's Earnings Yield (Greenblatt) (%) is ranked higher than
54% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.40 vs. SWTUY: 1.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SWTUY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 0.60 Max: 3.4
Current: 1.44
0.2
3.4

More Statistics

Revenue (TTM) (Mil) $434.9
EPS (TTM) $ 0.14
Beta1.93
Short Percentage of Float0.00%
52-Week Range $11.95 - 16.25
Shares Outstanding (Mil)267.63

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 778 972 1,245
EPS ($) 0.49 0.60 1.12
EPS without NRI ($) 0.49 0.60 1.12
EPS Growth Rate
(3Y to 5Y Estimate)
N/A

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)